AB Science SA
PAR:AB

Watchlist Manager
AB Science SA Logo
AB Science SA
PAR:AB
Watchlist
Price: 1.48 EUR 0.82% Market Closed
Market Cap: 97.9m EUR

Relative Value

The Relative Value of one AB stock under the Base Case scenario is 0.06 EUR. Compared to the current market price of 1.48 EUR, AB Science SA is Overvalued by 96%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

AB Relative Value
Base Case
0.06 EUR
Overvaluation 96%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
71
vs Industry
4
Median 3Y
99
Median 5Y
326.2
Industry
2.7
Forward
95.1
vs History
vs Industry
Median 3Y
-11.6
Median 5Y
-19.6
Industry
21.6
Forward
-11.1
vs History
vs Industry
Median 3Y
-13
Median 5Y
-16.1
Industry
16.9
vs History
vs Industry
Median 3Y
-19
Median 5Y
-45.6
Industry
22.9
vs History
vs Industry
Median 3Y
-4.3
Median 5Y
-11.4
Industry
2.3
vs History
69
vs Industry
4
Median 3Y
112.6
Median 5Y
331.4
Industry
3
Forward
108.7
vs History
69
vs Industry
2
Median 3Y
124.1
Median 5Y
410.7
Industry
5.6
vs History
vs Industry
Median 3Y
-18.7
Median 5Y
-24.7
Industry
13.4
Forward
-5
vs History
vs Industry
Median 3Y
-16.9
Median 5Y
-21.4
Industry
16.7
Forward
-5
vs History
vs Industry
Median 3Y
-14.5
Median 5Y
-18.2
Industry
16.1
vs History
vs Industry
Median 3Y
-14.2
Median 5Y
-17.3
Industry
18.9
vs History
66
vs Industry
4
Median 3Y
22.9
Median 5Y
22.7
Industry
2

Multiples Across Competitors

AB Competitors Multiples
AB Science SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
FR
AB Science SA
PAR:AB
97.9m EUR 95.4 -11.5 -24.9 -21.4
US
Eli Lilly and Co
NYSE:LLY
1T USD 16.9 54.6 36.7 39.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
491.8B USD 5.3 19.6 16 20.8
CH
Roche Holding AG
SIX:ROG
271.4B CHF 4.4 28.8 12.2 14.3
UK
AstraZeneca PLC
LSE:AZN
220.4B GBP 5.1 31.4 109 159.5
US
Merck & Co Inc
NYSE:MRK
274.9B USD 4.3 14.4 10.2 12.1
CH
Novartis AG
SIX:NOVN
218.8B CHF 4.9 19 12 15.5
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK 5.4 16.3 11.3 13.2
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
144.9B USD 2.3 14.7 7.5 10.2
P/E Multiple
Earnings Growth PEG
FR
AB Science SA
PAR:AB
Average P/E: 24.9
Negative Multiple: -11.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54.6
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.6
29%
0.7
CH
Roche Holding AG
SIX:ROG
28.8
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.4
37%
0.8
US
Merck & Co Inc
NYSE:MRK
14.4
15%
1
CH
Novartis AG
SIX:NOVN
19
17%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
16.3
3%
5.4
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.7
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
FR
AB Science SA
PAR:AB
Average EV/EBITDA: 440
Negative Multiple: -24.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36.7
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16
9%
1.8
CH
Roche Holding AG
SIX:ROG
12.2
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
109
10%
10.9
US
Merck & Co Inc
NYSE:MRK
10.2
6%
1.7
CH
Novartis AG
SIX:NOVN
12
6%
2
DK
Novo Nordisk A/S
CSE:NOVO B
11.3
1%
11.3
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
FR
AB Science SA
PAR:AB
Average EV/EBIT: 1 883.6
Negative Multiple: -21.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.3
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.8
15%
1.4
CH
Roche Holding AG
SIX:ROG
14.3
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
159.5
23%
6.9
US
Merck & Co Inc
NYSE:MRK
12.1
8%
1.5
CH
Novartis AG
SIX:NOVN
15.5
12%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
13.2
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
7%
1.5